Micro-RNAs (miRs) are short, noncoding RNAs that negatively regulate gene expression at the post-transcriptional level and have been implicated in the pathophysiology of secondary damage after traumatic brain injury (TBI). Among miRs linked to inflammation, miR-155 has been implicated as a pro-inflammatory factor in a variety of organ systems. We examined the expression profile of miR-155, following experimental TBI (controlled cortical impact) in adult male C57Bl/6 mice, as well as the effects of acute or delayed administration of a miR-155 antagomir on post-traumatic neuroinflammatory responses and neurological recovery. Trauma robustly increased miR-155 expression in the injured cortex over 7 days. Similar TBI-induced miR-155 expression changes were also found in microglia/macrophages isolated from the injured cortex at 7 days post-injury. A miR-155 hairpin inhibitor (antagomir; 0.5 nmol), administered intracerebroventricularly (ICV) immediately after injury, attenuated neuroinflammatory markers at both 1 day and 7 days post-injury and reduced impairments in spatial working memory. Delayed ICV infusion of the miR-155 antagomir (0.5 nmol/day), beginning 24 h post-injury and continuing for 6 days, attenuated neuroinflammatory markers at 7 days post-injury and improved motor, but not cognitive, function through 28 days. The latter treatment limited NADPH oxidase 2 expression changes in microglia/macrophages in the injured cortex and reduced cortical lesion volume. In summary, TBI causes a robust and persistent neuroinflammatory response that is associated with increased miR-155 expression in microglia/macrophages, and miR-155 inhibition reduces post-traumatic neuroinflammatory responses and improves neurological recovery. Thus, miR-155 may be a therapeutic target for TBI-related neuroinflammation.
Introduction
Micro-RNAs (miRs) are small (23 nucleotides) noncoding RNAs that regulate gene expression at a posttranslational level by binding to the 3′-untranslated region (UTR) of target messenger RNAs (mRNAs), thereby leading to their degradation and/or translational inhibition [1] . Among the numerous miRs, miR-155 has been extensively studied and has been implicated in inflammatory-associated processes (for review, see Dickey et al. [2] , Ponomarev et al. [3] , and Quinn and O'Neill [4] ). Specifically, miR-155 is upregulated in activated microglia and macrophages, serving to drive these cells towards a pro-inflammatory phenotype [5] . In microglia, knockdown of miR-155 by hairpin inhibitors (antagomirs) reduces the release of inflammatory mediators, including nitric oxide and pro-inflammatory cytokines [e.g., interleukin-1β (IL-1β), tumor necrosis factor-α (TNFα)], and attenuates microglial cellmediated neurotoxicity [6] . Furthermore, miR-155 has been shown to be involved in chemokine signaling, both in the periphery [7] [8] [9] [10] and within the central nervous system (CNS) [11] . Inhibition of miR-155 can attenuate toxic neuroinflammatory responses in the CNS [12] [13] [14] and improves neurological recovery in experimental models of multiple sclerosis (MS) [15] , amyotrophic lateral sclerosis (ALS) [16] , neuropathic pain [14] , spinal cord injury (SCI) [12] , Parkinson's disease (PD) [17] , and ischemic stroke [13, 18] .
Recent studies from our group, and others, demonstrate that experimental traumatic brain injury (TBI) increases expression of miR-155 in the injured cortex and hippocampus [19, 20] . Moreover, such injuries induce microglial cellmediated neuroinflammatory responses that are associated with neuronal loss and persistent neurological impairments [21, 22] . Given the documented pro-inflammatory role of miR-155 in neurodegenerative diseases, TBI-induced alteration of miR-155 in microglia may contribute to chronic neuroinflammation and related neurodegeneration. The aims of the present study were to 1) investigate the temporal profile of miR-155 expression in the injured cortex following experimental TBI in relation to microglial/macrophage activation and 2) evaluate the therapeutic potential of inhibiting miR-155 following TBI on long-term neuroinflammatory and neurobehavioral responses. We performed 2 molecular intervention studies using specific miR-155 hairpin inhibitors (antagomirs) that were delivered ICV either immediately after controlled cortical impact (CCI) in adult male C57Bl/6J mice or beginning at 24 h by continuous infusion using miniosmotic pumps. Molecular, histological, and neurobehavioral outcome measures were used to examine the effects of inhibiting miR-155 on post-traumatic neuroinflammatory responses and neurological recovery.
Methods

Animals
Studies were performed using adult male C57Bl/6J mice (10-12 weeks old) (Taconic Biosciences, Inc., Germantown, NY). Mice were housed in the animal care facility at the University of Maryland, School of Medicine, under a 12-h light-dark cycle, with ad libitum access to food and water. All surgical procedures were carried out in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Maryland School Of Medicine.
Study 1
Sham and CCI C57Bl/6J mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) at 1 h, 24 h, 72 h, and 7 days postinjury (n = 6/group) and transcardially perfused with ice-cold 0.9% saline (100 ml). Ipsilateral cortical tissue was rapidly dissected and snap-frozen on liquid nitrogen for RNA extraction. In a separate cohort of mice, sham and CCI C57Bl/6J mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) at 7 days post-injury (n = 6/group) and transcardially perfused with ice-cold 0.9% saline (100 ml). Ipsilateral cortical tissue was rapidly dissected and processed for cluster of differentiation 11b-positive selection of microglia/macrophages using MACS Separation Technology (Miltenyi Biotec, Auburn, CA) and snap-frozen on liquid nitrogen for RNA extraction.
Study 2
CCI C57Bl/6J mice (n = 5-6/group) received a single ICV injection of miR-155 antagomir or negative control antagomir at 15 min post-injury. Sham-injured C57Bl/6J mice served as controls. At 24 h following injury, mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) and transcardially perfused with ice-cold 0.9% saline (100 ml), and ipsilateral cortical tissue was rapidly dissected and snap-frozen on liquid nitrogen for RNA extraction and protein analysis.
Study 3
CCI C57Bl/6J mice (n = 8/group) received a single ICV injection of miR-155 antagomir or negative control antagomir at 15 min post-injury. Sham-injured C57Bl/6J mice served as controls. Spatial working memory was assessed using a Ymaze test at 7 days post-injury, immediately prior to euthanasia. Mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) and transcardially perfused with ice-cold 0.9% saline (100 ml), and ipsilateral hippocampal tissue was rapidly dissected and snap-frozen on liquid nitrogen for RNA extraction.
Study 4
CCI C57Bl/6J mice (n = 6-7/group) received a delayed continuous 6-day ICV infusion of miR-155 antagomir or negative control antagomir, via a mini-osmotic pump, beginning at 24 h post-injury. Sham-injured C57Bl/6J mice served as controls. At 7 days post-injury, mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) and transcardially perfused with ice-cold 0.9% saline (100 ml). Ipsilateral hippocampal tissue was rapidly dissected and snap-frozen on liquid nitrogen for RNA extraction.
Study 5
CCI C57Bl/6J mice (n = 12-15/group) received a delayed continuous 6-day ICV infusion of miR-155 antagomir or negative control antagomir, via a mini-osmotic pump, beginning at 24 h post-injury. Sham-injured C57Bl/6 mice served as controls. Motor function was assessed using the beam walk test on post-injury days (PIDs) 1, 3, 5, 7, 14, 21, and 28. Cognitive function was assessed using the Y-maze (spatial working memory; PID 11). At 28 days post-injury, mice were anesthetized (100 mg/kg sodium pentobarbital, I.P.) and transcardially perfused with ice-cold 0.9% saline (100 ml), followed by 300 ml of 4% paraformaldehyde. Brains were removed and post-fixed in 4% paraformaldehyde overnight, cryoprotected in 30% sucrose, and were processed for histological outcome measures.
Controlled Cortical Impact
Our custom-designed CCI injury device consists of a microprocessor-controlled pneumatic impactor with a 3.5-mm-diameter tip. Mice were anesthetized with isoflurane evaporated in a gas mixture containing 70% N 2 O and 30% O 2 and administered through a nose mask (induction at 4% and maintenance at 2%). Depth of anesthesia was assessed by monitoring respiration rate and pedal withdrawal reflexes. Mice were placed on a heated pad, and core body temperature was maintained at 37°C. The head was mounted in a stereotaxic frame, and the surgical site was clipped and cleaned with Nolvasan and ethanol scrubs. A 10-mm midline incision was made over the skull, the skin, and fascia were reflected, and a 4-mm craniotomy was made on the central aspect of the left parietal bone. The impounder tip of the injury device was then extended to its full stroke distance (44 mm), positioned to the surface of the exposed dura, and reset to impact the cortical surface. Moderate-level CCI was induced using an impactor velocity of 6 m/s and a deformation depth of 2 mm as previously described [22, 23] . After injury, the incision was closed with interrupted 6-0 silk sutures, anesthesia was terminated, and the animal was placed into a heated cage to maintain its normal core temperature for 45 min post-injury. Sham animals underwent the same procedure as TBI mice except for the impact.
Molecular Interventions
Acute ICV Administration
At 15 min post-injury, mice received a single ICV injection of miR-155 antagomir (0.5 nmol; GE Dharmacon, Lafayette, CO) or negative control antagomir (equal concentration; GE Dharmacon). All drugs were made up in artificial cerebrospinal fluid (aCSF) and were injected into the left lateral ventricle (coordinates from the bregma: posterior, − 0.5 mm; lateral, + 1.5 mm; ventral, − 2.0 mm) using a 30-gauge needle attached to a Hamilton syringe at a rate of 0.5 ml/min, with a final volume of 5 μl.
Delayed Continuous ICV Administration
Immediately prior to CCI, the right lateral ventricle was stereotaxically perforated with brain infusion kit 3 (ALZET, DURECT Corporation, Cupertino, CA; coordinates from the bregma: posterior, − 0.7 mm; lateral, − 1.5 mm; ventral, − 2.0 mm). At 24 h after moderate-level CCI on the left parietal cortex, the infusion cannula was connected to a mini-osmotic pump (ALZET; pump model 1007D) that was implanted subcutaneously in the animal's back, just behind the scapula. Osmotic pumps were primed for~8 h prior to implantation and were filled with miR-155 antagomir (0.5 nmol/day) or equal concentration of negative control antagomir. Once implanted, the pumps continually infused miR-155 antagomir or negative control antagomir for 6 days at a rate of 0.5 μl/h.
Isolation of Cluster of Differentiation 11b-Positive Cells
A magnetic bead-conjugated anti-cluster of differentiation 11b (CD11b) was used to isolate microglia/macrophages from ipsilateral cortical tissue using MACS Separation Technology (Miltenyi Biotec, Auburn, CA) as previously described [24] . Briefly, ipsilateral cortical tissues from sham and CCI mice were rapidly microdissected and a single cell suspension was prepared using enzymatic digestion (Neural Tissue Dissociation Kit; Miltenyi Biotec) in combination with a gentleMACS Dissociator. Myelin was removed using Myelin Removal Beads II and LS columns (Miltenyi Biotec), and cells were incubated with anti-CD11b MicroBeads (Miltenyi Biotec) and loaded onto a MS column (Miltenyi Biotec) placed in the magnetic field of a MACS separator. The negative fraction (flow through) was collected, and the column was washed 3 times with MACS buffer (Miltenyi Biotech). CD11b-positive cells were eluted by removing the magnetic field, resulting in the isolation of viable CD11b-positve cells (microglia/macrophages) from sham and CCI mice. Cells were snap-frozen on liquid N 2 for RNA extraction.
Real-Time PCR
Total RNA was extracted from the ipsilateral cortex and hippocampus of sham and CCI mice using a miRNeasy isolation kit (Qiagen, Valencia, CA) with on-column DNase treatment (Qiagen).
mRNA Expression
Complementary DNA (cDNA) synthesis was performed on 1 μg of total RNA using a Verso cDNA RT kit (Thermo Scientific, Pittsburg, PA); the protocols used were per the manufacturer's instructions. Real-time PCR for target mRNAs was performed using TaqMan gene expression assays [NADPH oxidase 2 (NOX2), Mm01287743_m1; human neutrophil cytochrome b light chain (p22 p h o x ), Mm00514478_m1; nitric oxide synthase 2 (NOS2), Mm00440502_m1; integrin subunit alpha M (ITGAM), Mm00434455_m1; CD68, Mm03047340_m1; TNFα, Mm00443258_m1; IL-1β, Mm01336189_m1; chemokine (C-C motif) ligand 2 (CCL2), Mm00441242_m1; chemokine (C-C motif) ligand 5 (CCL5), Mm01302427_m1; suppressor of cytokine signaling 1 (SOCS1), Mm00782550_m1; phosphatidylinositol-3-4-5-trisphosphate 5-phosphatase 1 ( S H I P -1 ) , M m 0 0 4 9 4 9 8 7 _ m 1 ; a n d G A P D H , Mm99999915_g1; Applied Biosystems, Carlsbad, CA] on an ABI 7900 HT FAST Real-Time PCR machine (Applied Biosystems). Samples were assayed in duplicate in 1 run (40 cycles), which was composed of 3 stages, 50°C for 2 min, 95°C for 10 s for each cycle (denaturation), and finally, the transcription step at 60°C for 1 min. Gene expression was normalized by GAPDH and compared to the control sample to determine relative expression values by the 2 −ΔΔCt method.
miR Expression
A total of 10 ng of total RNA was reverse transcribed using TaqMan miRNA Reverse Transcription Kit (Applied Biosystems) with miRNA-specific primers. Reverse transcription reaction products (2 μl) were used for real-time PCR as described above. The following TaqMan miR expression assays were used: miR-155-5p (002571) and endogenous control U6 small nuclear RNA (snRNA) (001973) (Applied Biosystems). miR-155 expression was normalized by U6 snRNA and compared to the control sample to determine relative expression values by the 2 −ΔΔCt method.
Western Blot Analysis
Proteins from the ipsilateral cortical tissue were extracted using RIPA buffer and were equalized and loaded onto 5-20% gradient gels for SDS PAGE (Bio-Rad; Hercules, CA) as previously described [25] . Proteins were transferred onto nitrocellulose membranes and then blocked for 1 h in 5% milk in 1× TBS containing 0.05% Tween 20 (TBS-T) at room temperature. The membrane was incubated in mouse anti-SOCS1 (1:500; BD Thermo Fisher, Waltham, MA), mouse anti-SHIP-1 (1:1000; CST, Danvers, MA), or mouse anti-β-actin (1:5000; Sigma-Aldrich) overnight at 4°C, then washed 3 times in TBS-T, and incubated in appropriate HRPconjugated secondary antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) for 2 h at room temperature. Membranes were washed 3 times in TBS-T, and proteins were visualized using SuperSignal West Dura Extended Duration
S u b s t r a t e ( T h e r m o S c i e n t i f i c , R o c k f o r d , I L ) .
Chemiluminescence was captured ChemiDoc XRS+ System (Bio-Rad), and protein bands were quantified by densitometric analysis using Bio-Rad Molecular Imaging software. The data presented reflects the intensity of target protein band normalized based on the intensity of the endogenous control for each sample (expressed in arbitrary units).
Immunofluorescence Imaging
Twenty-micrometer coronal brain sections from sham and CCI mice at~− 1.70 mm from the bregma were selected, and standard immunostaining techniques were employed. Briefly, 20-μm brain sections were washed 3 times with 1× PBS, blocked for 1 h in goat serum containing 0.4% Triton X-100, and incubated overnight at 4°C with a combination of primary antibodies, including mouse anti-gp91 phox (NOX2, 1:1000; BD Biosciences) and rat anti-CD68 (1:1000; AbD Serotec, Inc., Raleigh, NC). Sections were washed 3 times with 1× PBS and incubated with appropriate Alexa Fluorconjugated secondary antibodies (Life Technologies) for 2 h at room temperature. Sections were washed 3 times with 1× PBS, counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (1 μg/ml; Sigma, Dorset, UK), and mounted with glass coverslips using hydromount solution (National Diagnostics, Atlanta, GA). Images were acquired using a fluorescent Nikon Ti-E inverted microscope (Nikon Instrument, Inc., Melville, NY), at 10× (Plan Apo 10× NA 0.45) or 20× (Plan APO 20× NA 0.75) magnification. Exposure times were kept constant for all sections in each experiment. All images were quantified using Nikon ND-Elements software (AR 4.20.01). Colocalization of NOX2 and CD68 in microglia/ macrophage was performed by binary operation intersection followed by thresholding. Twelve positive regions of interest near the lesion site per mouse were quantified (with n = 5 mice/group) and expressed as NOX2
Stereology
Lesion Volume
Sixty-micrometer coronal sections from mice were stained with cresyl violet (FD NeuroTechnologies, Baltimore, MD), dehydrated, and mounted for analysis (n = 9/group). Lesion volume was quantified based on the Cavalieri method of unbiased stereology using Stereo Investigator software (MBF Biosciences, Williston, VT) as previously described [26] . Briefly, the lesion volume was quantified by outlining the missing tissue on the injured hemisphere using the Cavalieri estimator with a grid spacing of 0.1 mm. Every 8th section from a total of 96 sections was analyzed beginning from a random start point.
Neuronal Cell Loss
Cresyl violet-stained 60-μm coronal sections were used to quantify neuronal densities in the dentate gyrus region of the hippocampus of both sham and CCI mice. The optical fractionator method of stereology was employed as previously described [24] . Briefly, every 4th 60-μm section between − 1.22 and − 2.54 mm from the bregma was analyzed beginning from a random start point. A total of 5 sections were analyzed. The optical dissector had a size of 50 × 50 μm in the x-axis and the y-axis, respectively, with a height of 10 μm and a guard zone of 4 μm from the top of the section. The sampled regions of the dentate gyrus were demarcated in the injured hemisphere, and cresyl violet-positive cells were counted using Stereo Investigator software (MBF Biosciences). The volume of the dentate gyrus was measured using the Cavalieri estimator method with a grid spacing of 50 μm. The number of surviving neurons in each field was divided by the volume of the region of interest to obtain the cellular density expressed in counts/cubic millimeter.
Neurobehavioral Testing
Beam Walk
Motor function recovery was assessed using a beam walk test as previously described [27] . The beam walk test discriminates fine motor coordination differences between sham and CCI mice. The test consists of a narrow wooden beam (5 mm wide and 120 mm in length), which is suspended 300 mm above a tabletop. Mice were placed on 1 end of the beam, and the number of foot faults of the right hind limb was recorded over 50 steps. Mice were trained on the beam walk for 3 days prior to CCI and tested through 28 days post-injury.
Y-Maze Spontaneous Alternation
The Y-maze test assesses spatial working memory and was performed as previously described [23] . Briefly, the Y-maze (Stoelting Co., Wood Dale, IL) consisted of 3 identical arms, each arm 35 cm long, 5 cm wide, and 10 cm high, at an angle of 120°with respect to the other arms. One arm was randomly selected as the Bstart^arm, and the mouse was placed within and allowed to explore the maze freely for 5 min. Arm entries (arms A-C) were recorded by analyzing mouse activity using ANY-maze software (Stoelting Co., Wood Dale, IL). An arm entry was attributed when all 4 paws of the mouse entered the arm, and an alternation was designated when the mouse entered 3 different arms consecutively. The percentage of alternation was calculated as follows: total alternations × 100 / (total arm entries − 2). If a mouse scored > 50% alternations (the chance level for choosing the unfamiliar arm), this was indicative of spatial working memory.
Statistical Analysis
Randomization and blinding was performed as follows: a) individual who administered drugs was blinded to treatment group, and b) behavioral and stereological analyses were performed by individuals blinded to injury or treatment groups. Quantitative data were expressed as mean + standard error of the mean (SEM). Normality testing was performed and data sets passed normality (D'Agostino and Pearson omnibus normality test), and therefore, parametric statistical analysis was performed. Beam walk was analyzed by one-way repeated measures ANOVA to determine the interactions of time and groups, followed by post hoc adjustments using a Bonferroni's multiple comparison test. Y-maze and qRT-PCR were analyzed by one-way ANOVA, followed by post hoc adjustments using a Bonferroni's multiple comparison test. Stereological data were analyzed using a Student's t test (lesion volume) or one-way ANOVA (neuronal cell loss), followed by post hoc adjustments using the StudentNewman-Keuls test. Statistical analyses were performed using GraphPad Prism program, version 3.02 for Windows (GraphPad Software, San Diego, CA, USA). A p value < 0.05 was considered statistically significant.
Results
TBI Increases miR-155 Expression in Microglia/Macrophages in the Injured Cortex and Results in a Pro-inflammatory Activation Response
We induced moderate-level CCI in adult male C57Bl/6J mice and collected ipsilateral cortical tissue at 1 h, 24 h, 72 h, and 7 days post-injury for miR-155 expression analysis. When compared to sham control levels, there was a significant increase in miR-155 expression starting at 24 h post-injury (p < 0.001; Fig. 1a ) that persisted through 7 days post-injury (p < 0.001 vs sham). We next isolated microglia/macrophages from the sham and injured cortex at 7 days post-injury using anti-CD11b MicroBeads and MACS technology [24] . miR-155 expression levels were robustly increased in enriched microglia/macrophages from the ipsilateral cortex when compared to sham-injured controls (> 5-fold increase; p < 0.01 vs sham; Fig. 1b) . Furthermore, isolated microglia/macrophages had a pro-inflammatory phenotype, with significantly increased expression of CD68 (p < 0.001), IL-1β (p < 0.001), CCL5 (p < 0.001), and p22 phox (p < 0.01) mRNA when compared to isolated microglia/macrophages from sham controls (Fig. 1b) . Other pro-inflammatory markers (TNFα, NOX2) were also increased in microglia/macrophages from the injured cortex but failed to reach statistical significance (data not shown).
Acute ICV Administration of miR-155 Antagomir Attenuates TBI-Induced Pro-inflammatory Gene Expression in the Cortex
Next, moderate-level CCI mice were administered miR-155 antagomir (0.5 nmol) or equal concentration of negative control antagomir by single ICV injection in the ipsilateral lateral ventricle at 15 min post-injury, and cortical tissue was isolated at 24 h post-injury for analysis of miR-155, its direct targets, and pro-inflammatory cytokines. As predicted, there was a significant increase in miR-155 expression in the ipsilateral cortex at 24 h post-injury (p < 0.05 vs sham; Fig. 2a) . Notably, when TBI mice were administered miR-155 antagomir, there was a significant decrease in cortical miR-155 expression when compared to TBI mice that received negative control antagomir treatment (p < 0.05; Fig. 2a) . In addition, acute ICV administration of miR-155 antagomir also significantly reduced TBI-induced expression of IL-1β in the injured cortex (p < 0.05 vs TBI + neg control antagomir; Fig. 2a ) and reduced TNFα expression, albeit nonsignificantly. We next assessed levels of known miR-155 direct targets, SOCS1 [28] and SHIP-1 [29] , in the sham and injured cortex. TBI resulted in a significant reduction in SOCS1 mRNA and protein levels in the injured cortex at 24 h post-injury [p < 0.05 (mRNA) and p < 0.001 (protein) vs sham; Fig. 2b ]. TBI mice that received miR-155 antagomir treatment had elevated SOCS1 mRNA levels at 24 h post-injury compared to the negative control antagomir-treated TBI group, but these failed to reach statistical significance. Furthermore, neither injury nor miR-155 antagomir treatment altered predicted target SHIP-1 mRNA or protein levels at 24 h post-injury (Fig. 2b) .
Acute ICV Administration of miR-155 Antagomir Attenuates TBI-Induced Pro-inflammatory Gene Expression in the Hippocampus and Improves Cognitive Function Recovery in Injured Mice
In a follow-up study, moderate-level CCI mice were administered miR-155 antagomir (0.5 nmol) or equal concentration of negative control antagomir by single ICV injection in the ipsilateral lateral ventricle at 15 min post-injury, and animals underwent cognitive testing at 7 days post-injury prior to tissue isolation for mRNA analysis. When we assessed hippocampus-dependent spatial working memory using the Y-maze test, sham mice showed 80.4 ± 4.4% spontaneous alteration, indicative of functional working memory. TBI resulted in a significant decrease in spontaneous alternation (60.3 ± 5.2%) in TBI mice treated with negative control antagomir (p < 0.05 vs sham; Fig. 3a) . Notably, acute central administration of miR-155 antagomir in TBI mice reduced injury-induced deficits in cognitive function (p < 0.5 vs TBI + neg control antagomir), such that miR-155 antagomirtreated TBI mice had similar spontaneous alternation activity as sham mice. The total arm entries for each group of mice were identical in this test. We next assessed hippocampal expression of genes associated with microglial/macrophage activation and pro-inflammatory neuroinflammatory responses, including ITGAM, CD68, NOS2, p22 phox , NOX2, and TNFα. TBI resulted in significantly increased neuroinflammatory gene expression in TBI mice treated with negative control antagomir when compared to sham levels (p < 0.05, p < 0.001 vs sham; Fig. 3b ). miR-155 antagomir treatment significantly decreased TBI-induced expression of ITGAM (p < 0.001), NOS2 (p < 0.01), NOX2 (p < 0.001), and p22 phox (p < 0.001 vs TBI + neg control antagomir), whereas there was a nonsignificant reduction in TNFα expression.
Delayed ICV Administration of miR-155 Antagomir Starting at 24 h Post-injury Attenuates Post-traumatic Neuroinflammatory Responses at 7 Days Post-injury
We next investigated whether a delayed and more clinically relevant treatment paradigm could be effective in ameliorating neuroinflammatory responses following TBI. Moderate-level CCI mice received a continual infusion of a miR-155 antagomir (0.5 nmol/day) or equal concentration of negative control antagomir via contralateral ICV administration using ALZET pumps, beginning at 24 h post-injury and continuing through 7 days post-injury. Administration of the miR-155 antagomir significantly decreased TBI-induced upregulation of miR-155 in the hippocampus at 7 days post-injury (p < 0.05 vs TBI + neg control antagomir; Fig. 4) . Furthermore, miR-155 antagomir treatment reduced expression of proinflammatory and microglial/macrophage activation genes in the hippocampus, including ITGAM (p < 0.05), CD68 (p < 0.05), NOX2 (p < 0.05), p22 phox (p < 0.05), TNFα (p < 0.05), and CCL2 (p < 0.05 vs TBI + neg control antagomir; Fig. 4 ). There was a reduction in IL-1β and CCL5 expression with delayed miR-155 antagomir treatment; however, these changes failed to reach statistical significance.
It is important to note that while there were significant TBIinduced increases in miR-155 and pro-inflammatory gene expression in the ipsilateral cortex of negative control antagomir-treated TBI mice at 7 days post-injury, these proinflammatory markers were not attenuated by miR-155 (Table 1) . Furthermore, miR-155 antagomir treatment did not alter TBI-induced expression of miR-155 direct targets, SHIP-1 or SOCS1, in the ipsilateral cortex at 7 days post-injury (Table 1) .
Delayed ICV Administration of miR-155 Antagomir Improves Long-Term Motor But Not Cognitive Function After TBI
To determine whether miR-155 inhibition could improve neurological function following TBI, we repeated the delayed and continuous miR-155 antagomir infusion protocol in a separate cohort of CCI mice and followed animals for 28 days postinjury. We assessed motor and cognitive function recovery using beam walk and Y-maze behavioral tests, respectively. First, we performed beam walk to assess deficits in fine motor coordination. When compared to sham mice, TBI resulted in significant motor function impairments in negative control antagomir-treated TBI mice, with 50 ± 0 foot faults (FFs; mean ± SEM) at 1 day post-injury and persistent foot faults through 28 days post-injury (39 ± 6 FFs; p < 0.001 vs sham; Fig. 5a ). Delayed administration of miR-155 antagomir significantly improved motor function recovery after TBI, with miR-155 antagomir-treated mice having 30 ± 3 and 29 ± 3 foot faults at 14 days and 21 days post-injury, respectively (p < 0.05 vs TBI + neg control antagomir). We then assessed hippocampus-dependent spatial working memory using the Y-maze test. When compared to % spontaneous alternation in sham mice (74.0 ± 4.5%), TBI significantly decreased spontaneous alternations (65.6 ± 2.9%) in TBI mice treated with negative control antagomir (p < 0.05 vs sham; Fig. 5b ). Delayed administration of the miR-155 antagomir failed to improve spatial working memory in this test, and miR-155 antagomir-treated TBI mice had equivalent spontaneous alternation activity (60.7 ± 3.9%) as negative control antagomir-treated TBI mice.
Delayed ICV Administration of miR-155 Antagomir Reduces TBI-Induced Cortical Lesion Volume and the Number of Reactive Microglia/Macrophages in the Injured Cortex
Next, we quantified TBI-induced lesion volume in the ipsilateral cortex of miR-155 antagomir and negative control antagomir-treated TBI mice at 28 days post-injury. The lesion volume of negative control antagomir-treated TBI mice was 8.62 ± 1.10 mm 3 (Fig. 6a) . Notably, the delayed miR-155 antagomir treatment significantly reduced the lesion to 6.56 ± 0.73 mm 3 (p < 0.05 vs TBI + neg control antagomir). TBI in negative control antagomir-treated TBI mice also resulted in significant neuronal loss in the dentate gyrus when compared to sham levels (p < 0.05 vs sham; Fig. 6b ). However, delayed miR-155 antagomir treatment failed to rescue TBI-induced neuronal loss in the dentate gyrus.
We finally evaluated NOX2 expression in reactive microglia/macrophages that coexpressed CD68, a marker of highly phagocytic activity, in the injured cortex. TBI induced robust NOX2 expression in CD68 + cells that displayed amoeboid morphological features in the cortex of negative control antagomir-treated TBI mice (Fig. 7a, b) . Notably, delayed administration of miR-155 antagomir significantly reduced the number of NOX2
+ microglia/macrophages in the injured cortex (p < 0.05 vs TBI + neg control antagomir).
Discussion
We have previously shown that sustained microglial activation after brain trauma contributes to subsequent progressive neurodegeneration and associated neurological deficits [21] [22] [23] [24] [25] . Consistent with recent findings [30] , we demonstrate that miR-155 rapidly and progressively increases in the ipsilateral cortex through 7 days post-injury. In an earlier study, we demonstrated increased post-traumatic expression of miR- Data are expressed as mean + SEM (one-way ANOVA, with Bonferroni post hoc adjustment). N = 6-7/group *p < 0.05; **p < 0.01 vs sham counterparts 155 in the injured cortex at 24 h that was associated with elevated expression of several pro-inflammatory genes (NOS2, TNFα, IL-1β, IL-6, and CCL2) [19] . Here, we confirmed that microglia/macrophages isolated from the injured cortex show increased miR-155 expression that was associated with elevations in markers of microglial/macrophage activation and pro-inflammatory signaling-including IL-1β, TNFα, CCL5, and NADPH oxidase subunits (NOX2, p22 phox ). The expression level of ROS-producing NOX2 is highly elevated in reactive microglia/macrophages (NOX2 + /TNFα + / CD68 + ) in the injured cortex at the peak of neuroinflammation in this model (7 days post-injury) and remains elevated for several months [22, 23, 31] . Similar to the observed therapeutic effects in the current study, pharmacological inhibition of NOX2 starting at 24 h post-injury shifts microglia/macrophages towards an anti-inflammatory phenotype, which is associated with reduced oxidative damage in neurons and improved neurological recovery [23, 24] . miR-155 is a critical regulator of Toll-like receptor (TLR) 3 and 4 and interferon (IFN)-γ-mediated signaling in macrophages [32] [33] [34] [35] . In addition, macrophages from miR-155 knockout or from wild-type mice treated with a miR-155 oligonucleotide inhibitor show decreased expression of proinflammatory markers including NOX2, TNFα, and IL-1β [32] . miR-155 is also robustly upregulated in activated microglia and promotes a pro-inflammatory phenotype [5, 36] . Notably, miR-155 knockout microglia or antimiR-155 oligonucleotides reduce nitric oxide and proinflammatory cytokines in response to lipopolysaccharide stimulation (TLR4 ligand), as well as suppress microglial cell-mediated neurotoxicity in coculture model systems [6] . In the present study, we demonstrate that inhibiting miR-155 in the early post-traumatic period, using single-dose ICV administration of miR-155 antagomir, decreases microglial/macrophage activation and pro-inflammatory signaling in the injured cortex and hippocampus at 1 day and 7 days post-injury, respectively. This attenuation of the post-traumatic neuroinflammatory response was associated with reduced impairments in spatial working memory.
In order to minimize toxicity, we administered the miR-155 antagomir (inhibitory oligonucleotides) in vivo without additional transfection reagents [37] . Although prior reports, such as those by Reschke et al. [38] , used modifications of the oligonucleotides (e.g., cholesterol) to improve their ability to penetrate cellular membranes without additional transfection reagents, other studies suggest that the range of miR-targeting oligonucleotides that can independently penetrate membranes may be larger than previously thought. For example, Morris et al. [39] used phosphorothioate (PS)-modified backbones (Power Inhibitors) without transfection reagents to silence their target miRs in the brain following intracerebroventricular injection. Moreover, Stein et al. [37] describe the process of unassisted Bnaked^delivery of oligonucleotides, coining the term Bgymnosis^; although these authors focused their studies on PS-containing oligonucleotides, they note that additional modification may also contribute to gymnosis, including 2′-O-methyl modifications. The Dharmacon-produced oligonucleotides that were used in our TBI studies include 2′-Omethyl modifications, as detailed in a prior publication linked to their patent [40] . Other studies have reported on gymnosis in modulating miRs; 2′-O-methyl modifications, such as an oligonucleotide produced by Dharmacon, showed miR inhibitory activity in the absence of transfection reagents [41] . Although the mechanisms underpinning gymnosis have yet to be fully elucidated, we believe that this process may account, at least in part, for the ability of the miR-155 oligonucleotides used in our studies to penetrate the cellular membrane and target intracellular signaling in the absence of transfection reagents. Another possible mechanism that may increase membrane permeability for therapeutic delivery of miR antagomirs involves post-traumatic mechanoporation [42] [43] [44] . A challenge for developing translational neuroprotective treatment strategies in TBI is identifying targets for pharmacological intervention that have a long therapeutic window [45] . Chronic microglial activation and molecular mechanisms underlying secondary neuroinflammation are recognized as potential therapeutic targets for severe TBI [46] . Therefore, to test a more clinically relevant treatment paradigm, we evaluated delayed administration of the miR-155 antagomir, starting at 24 h post-injury and continuing for 6 days. Such treatment significantly reduced miR-155 levels in the injured hippocampus at 7 days and attenuated TBIinduced increased expression of markers of microglial/ macrophage activation and pro-inflammatory signaling. Inhibition of miR-155 also decreased TBI-induced chemokine expression, including CCL2. Morganti and colleagues [47] recently demonstrated that inhibition of CCL2-CCR2 signaling following TBI, using a selective CCR2 antagonist, attenuated pro-inflammatory signaling. These effects were associated with improved hippocampus-dependent learning and memory at 28 days post-injury [47] . CCR2 knockout mice also show reduced lesion volume and decreased neuroinflammation at 3 days following severe CCI [48] . CCL5 is robustly upregulated acutely after TBI in mice [49] and humans [50] ; elevated levels of CCL5 in plasma of TBI patients at admission correlate with poor outcome [51] . Here, we demonstrated that moderate-level TBI increases CCL2 and CCL5 expression at 7 days post-injury, and that delayed inhibition of miR-155 attenuates both CCL2 and CCL5 levels. Notably, leukocyte-specific deletion of miR-155 reduces the expression of CCL2 in pro-inflammatory macrophages, which results in recruitment of monocytes to clear atherosclerotic plaques and attenuate vascular inflammation in mouse models of atherosclerosis [52] . To our knowledge, this is the first study linking miR-155 and chemokine signaling (CCL2/CCL5) in the context of macrophage/microglial activation after experimental TBI.
Delayed miR-155 antagomir treatment also improved fine motor coordination in TBI mice at 14 days and 21 days, but not at 28 days. The absence of significant effects at the latter time point may reflect washout of miR-155 antagomir from the CNS over time. Furthermore, unlike the acute miR-155 treatment paradigm, delayed inhibition of miR-155 failed to reduce TBI-induced impairments of hippocampus-dependent working memory in the Y-maze test and did not reduce + microglia/macrophages in the injured cortex.
The miR-155-induced pro-inflammatory response has been linked, in part, to suppression of its predicted targets including SOCS1 [6, 13, 53] and SHIP-1 [13, 54] . SOCS1 is a negative regulator of IFN signaling and a validated target of miR-155 that functions to inhibit STAT1 [30] , a key transcription factor for IFN signaling, whereas SHIP-1 helps control immune cell function by downregulating PI3K signaling pathways [55] . The links among miR-155 expression, SOCS-1 and SHIP-1 inhibition, and production of inflammatory mediators in myeloid cells suggest that the deregulation of miR-155 can drive progressive neuroinflammation by disturbing the protective function of SOCS1/SHIP-1, increasing pro-inflammatory cytokine and nitric oxide production [6, 13, 53, 54, 56] . TBI significantly reduced SOCS1, but not SHIP-1, in the injured cortex at 24 h post-injury. Treatment with the miR-155 antagomir attenuated the post-traumatic decrease of SOCS1, with mRNA levels not significantly different from sham control levels. However, SOCS1 protein levels did not differ between miR-155 antagomir and negative control antagomir treatment groups at 24 h. This time point may be too early to detect protein changes. Decreased SOCS1 mRNA expression has been reported in miR-155 knockout mice subjected to moderate-level CCI as compared to wild-type CCI mice [30] . However, the results in miR-155 knockout mice contrast with ours and those in experimental stroke, where miR-155 inhibitors administered to distal middle cerebral artery occlusion (dMCAO) mice upregulate SOCS1 and SHIP-1 in the injured cortex at 7 days post-injury, a time point that was associated with robust anti-inflammatory activity [13] . The effects of miR-155 inhibitors on SOCS1/SHIP-1 in the dMCAO model were lost at later time points (14 days postinjury), suggesting that dosing and duration of miR-155 antagomir treatment may be relevant for optimal neuroprotection in CNS injury models. Further translational studies, including dose-response and treatment duration, will be needed to optimize the anti-inflammatory and neuroprotective effects of miR-155 antagomir treatment after TBI. Perhaps surprisingly, central administration of miR-155 antagomir attenuated TBI-induced miR-155 elevation in the injured cortex. However, this observation is consistent with prior work demonstrating that inhibitor-induced miR degradation can occur under certain conditions [57] . It is also possible that the miR-155 reduction observed in our TBI study reflects an indirect effect in which miR-155 inhibition/sequestration in an early cell subpopulation may reduce propagation of proinflammatory secondary injury responses that limit later miR-155 induction.
Our study revealed region-specific anti-inflammatory effects of miR-155 antagomir in the injured cortex and hippocampus. Possible reasons for region-specific responses may include site of injection for miR-155 antagomirs and/or increased sensitivity of the hippocampus to miR-155-based treatments. When we infused miR-155 antagomir into the contralateral ventricle using a 7-day mini-osmotic pump (inserted at 24 h post-injury) infusion, there were reduced miR-155 expression and decreases of various proinflammatory and microglial cell-related markers in the ipsilateral hippocampus at 7 days post-injury. However, the ipsilateral cortex of these mice did not show changes in the expression of miR-155 or pro-inflammatory markers. The antiinflammatory effects in the hippocampus may reflect increased access of the miR-155 antagomir under these conditions, as this region is closer to the infusion site than the ipsilateral cortex tissue examined. An alternative explanation for site-specific effects may be that several miR-155 targets are highly expressed in the hippocampus [58, 59] , thus possibly indicating that the hippocampus is more sensitive to modulation by miR-155. The fact that genetic ablation of miR-155 is associated with a decrease of inflammatory-mediated impairments in neurogenesis following systemic LPS challenge [59] may be consistent with the latter interpretation.
A recent study reported exacerbation of hippocampal neurodegeneration, as well as increased microglial/macrophage activation, in miR-155 knockout mice following CCI [30] . Such apparently divergent results may reflect cell-specific responses and/or compensatory effects due to use of a constitutive miR-155 knockout model. Thus, Harrison and colleagues [30] reported that miR-155 was upregulated in hippocampal neurons at 24 h post-injury. Further studies addressing cellspecific modulation of miR-155 using miR-155 fl/fl transgenic models [60] will be needed to address this apparent discrepancy. Another potentially important issue is the role of miR-155 in mitochondrial dysfunction after CNS injury, given that administration of a miR-155 mimic can cause mitochondrial dysfunction in macrophages [61] . In addition, miR-155 has been reported to be markedly upregulated in isolated mitochondria from the hippocampus at 12 h post-injury [20] . Moreover, it was recently shown that pro-inflammatory cytokines increase miR-155 levels in the hippocampus after TBI, which suppressed peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) mRNA, altering mitochondrial biogenesis and possibly mitochondrial respiratory dysfunction [62] . Given the rapid onset of mitochondrial dysfunction following TBI (within minutes), if miR-155 contributes to such deficits, this may help explain the apparently less effective therapeutic response to delayed treatment.
In summary, we demonstrate that moderate-to-severe TBI causes increased miR-155 expression in microglia/macrophages, and that selective miR-155 inhibition reduces posttraumatic neuroinflammatory responses and behavioral dysfunction. Thus, miR-155 should be considered as a potential therapeutic target in head injury.
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